ART Advanced Research Technologies Inc.: SoftScan Breast Cancer Imaging Device Featured in Academic Radiology Peer-Reviewed Journal.MONTREAL -- ART Advanced Research Technologies Inc. ("ART") (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension :ARA Ara or Arrah (both: ŭ`rə), city (1991 pop. 157,082), Bihar state, NE India, on the Son Canal. A major road and rail junction, it is the administrative center for a district that produces grain, sugarcane, and oilseed. ), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, today announced that results from an engineering optimization study conducted at the Cedars Breast Center of the Royal Victoria Hospital For other places with the same name, see Royal Victoria Hospital (disambiguation). The Royal Victoria Hospital at 687 Pine Avenue West in Montreal, Quebec, Canada was established in 1893, through the financial contributions of two Scottish immigrants, Donald Smith and George in Montreal, Quebec, Canada, under the supervision of Dr. David Fleiszer, have been published in the August issue of Academic Radiology.The article, entitled "Time-Domain Optical Mammography mammography, diagnostic procedure that uses low-dose X rays to detect abnormalities in the breasts. The early diagnosis of breast cancer made possible by the routine use of mammography for screening women increases a woman's treatment alternatives and improves her SoftScan(R): Initial Results", illustrates the sensitivity of near-infrared (NIR NIR Near Infrared NIR National Inventory Report NIR National Identity Register (UK) NIR Near-Infrared Reflectance NIR Non-Ionizing Radiation NIR Net International Reserves NIR National Internet Registry NIR Northern Ireland Railways ) optical techniques to the metabolic functions of breast tissue.Using the non-invasive SoftScan system, 49 women underwent tests resulting in statistically significant discrimination of malignant and benign tissue based on their deoxy-hemoglobin content. "This study is of real interest to the breast cancer research community, since the capacity offered by the SoftScan system in discriminating between malignant and benign breast lesions is of great importance to clinicians", commented Micheline Bouchard, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of ART. About the trial In the 49-patient study, representing a wide cross-section of demographic factors, patients had either abnormal or normal mammograms before undergoing the SoftScan procedure.Patients' ages ranged between 24 and 80 years and included subjects who had undergone hormone replacement therapy Hormone Replacement Therapy Definition Hormone replacement therapy (HRT) is the use of synthetic or natural female hormones to make up for the decline or lack of natural hormones produced in a woman's body. or hysterectomy hysterectomy (hĭstərĕk`təmē), surgical removal of the uterus. A hysterectomy may involve removal of the uterus only or additional removal of the cervix (base of the uterus), fallopian tubes (salpingectomy), and ovaries , or had dense breasts. Results In all cases imaged with suspicious masses, the optical images obtained with SoftScan were consistent with mammographic findings. Furthermore, consistent differences are found between malignant and benign pathologies.Malignant lesions clearly exhibited a higher deoxy-hemoglobin content compared to surrounding tissue than benign cases.These findings are consistent with the observation that malignant tumors are more metabolically active than benign lesions. Reprints available upon request by contacting ART Advanced Research Technologies directly or through the Academic Radiology web site at www.academicradiology.org . About ART ART Advanced Research Technologies Inc. is a leader in optical molecular imaging products for the healthcare and pharmaceutical industries. ART has developed two products based on its innovative technology. The first is eXplore Optix(TM), a molecular imaging device designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs.eXplore Optix(TM) is distributed by GE Healthcare GE Healthcare is a $18 billion (USD) unit of General Electric (GE). It employs more than 46,000 people worldwide and is headquartered in Chalfont St. Giles, Buckinghamshire, United Kingdom. GE Healthcare is the first GE business segment headquartered outside the United States. and is used by industry and academic leaders worldwide to bring new and better treatments to patients faster. The second is SoftScan(R), a medical imaging device designed to improve the diagnosis and treatment of breast cancer. ART is commercializing its products in a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. ART's shares are listed on the TSX under the ticker symbol Ticker Symbol An arrangement of characters (usually letters) representing a particular security listed on an exchange or otherwise traded publicly. When a company issues securities to the public marketplace, it selects an available ticker symbol for its securities which investors ARA. Visit ART online at www.art.ca This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in ART Advanced Research Technologies Inc.'s regulatory filings with Canadian Securities Commissions and the Securities and Exchange Commission in the United States. ART ADVANCED RESEARCH TECHNOLOGIES INC. (TSX:ARA) |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion